Catalyst Wire Dossier Catalyst Wire Dossier

IVIg 10%

intravenous immunoglobulin · Kedrion S.p.A.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IVIg 10%, covering 2022-01-27 to 2026-01-15. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) [Phase 3]

See pricing